Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05923411 · ClinicalTrials.gov registry record · Phase 1
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
A Phase 1 study of Healthy Participants, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 1
- Study location
NCT05923411: Completed Phase 1 study of Healthy Participants, sponsored by Pfizer.
NCT05923411 is a Phase 1 study of Healthy Participants that has completed, run by Pfizer. The registered enrollment target is 113 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (74% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05923411, a Phase 1 study of Healthy Participants, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare multiple formulations of PF-07220060 in terms of their uptake into the blood stream. The study will assess the effects of food and Rabeprazole on the uptake of PF-07220060. Rabeprazole belongs to a type of medications called proton pump inhibitors. In reality, some patients may take both PF-07220060 and rabeprazole together. This study is seeking participants that are: \- Healthy male or female aged 18 to 65 years Participants in this study will receive PF-07220060 once or twice by mouth. The participants may receive different tablets for PF-07220060. Some participants will take a meal before receiving PF-07220060. In addition, some participants will take rabeprazole by mouth for 7 days before taking PF-07220060. The study will compare experiences of people receiving different formulations of PF-07220060. Experiences of people taking food and rabeprazole with PF-07220060 will be compared to those on PF-07220060 alone. This will help understand how much PF-07220060 is taken up into the blood. It will also help understand how meal and Rabeprazole medicine changes the uptake of PF-07220060 into the blood. Participants will take part in the study for a maximum of 74 days. During this time, they will have to stay onsite for 5 to 13 days. There will be up to 2 onsite study visits.
Conditions Studied
Interventions
- DRUG Single dose of PF-07220060 as first Tablet Formulation
- DRUG Single dose of PF-07220060 as second Tablet Formulation
- DRUG Single dose of PF-07220060 as a Tablet Formulation
Study Locations (1)
Connecticut
- New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2024-07-19 |
| Phase | Phase 1 |
What the finished NCT05923411 record still lists
NCT05923411 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Single dose of PF-07220060 as first Tablet Formulation is the first listed.
NCT05923411 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05923411 about?
NCT05923411 is a clinical study titled "A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults". The purpose of this study is to compare multiple formulations of PF-07220060 in terms of their uptake into the blood stream. The study will assess the effects of food and Rabeprazole on the uptake of PF-07220060. Rabeprazole belongs to a type of medications called proton pump inhibitors. In reality,...
What is the current status of trial NCT05923411?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2023-07-11. Estimated completion is 2024-07-19.
What conditions does trial NCT05923411 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT05923411?
The interventions under investigation include: Single dose of PF-07220060 as first Tablet Formulation (DRUG), Single dose of PF-07220060 as second Tablet Formulation (DRUG), Single dose of PF-07220060 as a Tablet Formulation (DRUG).
Who is sponsoring clinical trial NCT05923411?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05923411 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05923411's enrollment target sits among peer trials
113 18th of 119 higher than 102 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI